Drugs / Lepetegravir
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT06613685 | Oct 2024 → Mar 2026 | HIV infectious disease | Gilead Sciences | Terminated | No outcome recorded Stop: Business |
| Phase 2/3 | NCT06544733 | Aug 2024 → Jan 2028 expected | HIV infectious disease | Gilead Sciences | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-11-12 | Gilead Sciences | Results Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline gilead.com ↗
In new outcomes presented at HIV Glasgow, the pharmacokinetics and resistance data of GS-1720 were evaluated in a phase 1b study ( NCT05585307 ). |
| 2024-03-05 | Gilead Sciences | Results Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health gilead.com ↗
The data presented at the 31st Conference on Retroviruses and Opportunistic Infections ( CROI ) demonstrate Gilead’s commitment to advancing the next wave of biomedical innovations in HIV to address the unmet needs of people with the virus and help end the epidemic worldwide. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-11-12 | Gilead Sciences | Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline gilead.com ↗ |
| 2024-03-05 | Gilead Sciences | Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health gilead.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lepetegravir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06544733 ↗ |
| Action | Inhibit | “an oral, long-acting integrase strand transfer inhibitor (INSTI)” NCT06613685 ↗ |
| Route | Oral | “Tablets administered orally without regard to food” NCT06613685 ↗ |